DEPARTMENT OF ENDOCRINOLOGY, DIABETES & METABOLISM

CHRISTIAN MEDICAL COLLEGE - VELLORE



AGPAT2, BSCL2, INSR, LMNA, PPARY & ZMPEST24 PANEL NEXT GENERATION SEQUENCING BASED STRATEGY



Patient Information

health condition. Please circle: Yes/No

related research. Please circle: Yes/No

Patient's Signature:

Name: Address:			Hospital No. : Age: Ethnic Origin:	Sex:
Phone: E-m	nail:		Education: Occupation:	
History	· · · · · · · · · · · · · · · · · · ·		·	
DM: Yes/No Initial Type: Treatment details:		Age at diagnosis:	Current treatm	ent: OAD/Insulin
Signs of weight loss at onset:			Age a	t onset:
Weight gain over abdomen: Yes/No			Selective weight loss	
Progression of weight loss over yea	ars		Colocato Wolghanes	
H/O PCOS: Yes/No Menstrual History: I	M Id I	d l regular/irregu	ular I average/increased	/decreased flow
H/O Jaundice: Yes/No CVS: Normal/Breathlessness/Angina/Syncope/Palpitations/Oth				
H/O Hypertension: Yes/No	Hypertension: Yes/No H/O Frothy urin		: Yes/No H/O Pedal Oedema: Yes/No	
Other relevant history:				
Mentally challenged: No/Mild/Moderate/S	Severe			
Family history of similar illness: Yes/No	If Yes n	nention relation:		
Approximate calorie intake per day: Diet: Veg.		lon-veg	Appetite: Normal/Decreased/Increased	
Alcohol consumption: Yes/No	·		Amount per week:	
Smoking: Yes/No	Duration:		Pack years	:
Examination				
Initial Weight: Current weight				
	mm Hg	Icterus: Yes/No	Pedal Oedema: Yes/No	
General Appearance: Normal/Cushingoid/Acromegalic/Progeroid/Other Umbilical prominence: Y				
Muscular hypertrophy: Yes/No Phlebomegaly: Yes/No Hirsuitism/Virilism: Yes/Acanthosis nigricans: Yes/No Grade: I/II/III Hepatomegaly: Yes/No Abdominal circumference:				
Acanthosis nigricans: Yes/No Grade Normal skin: Yes/No If not, elaborate:	. 1/11/111 nep	atomegaly. Yes/No	Abdominal circum	ierence:cm
Other findings pertaining to the clinical diag	gnosis:			
Biochemistry				
Haemoglobin: GRBS:	a. c./p. c.:	HbA1	C: Insulin	(fasting):
	•		min p. c.):	LDL:
HDL: Triglycerides: Tot	al Cholesterol:	Albumin:		Bilirubin:
Direct Bilirubin: SGOT:	SGPT:	Creatinine:	Uri	ne ACR:
Consent				
 I have understood that my blood sample 	e will be used for c	liagnostic and resea	rch purposes relevant to	o my

I also give my consent to contact me at the address mentioned above regarding my genetic test report and

Witness' Signature:

DEPARTMENT OF ENDOCRINOLOGY, DIABETES & METABOLISM



AGPAT2, BSCL2, INSR, LMNA, PPARY & ZMPEST24 PANEL NEXT GENERATION SEQUENCING BASED STRATEGY



Pedigree

(Draw a pedigree chart with details of 3-4 generation affected members, sample code and hospital no.)	ns, age of onset, treatment details, complications, proband name, contact no. of	
Overview		
Diabetes Mellitus	Early onset/Late onset/No	
Features of insulin resistance	Yes/No	
Selective adipose tissue loss	Yes/No	
Localised pattern of fat loss	Yes/No	
Associated autoimmunity	Yes/No	
Pattern of inheritance	Autosomal dominant/autosomal recessive/indefinite/none	
Justify if not fitting into the clinical criteria of	r provide relevant clinical information	

Doctor's signature:

DEPARTMENT OF ENDOCRINOLOGY, DIABETES & METABOLISM

CHRISTIAN MEDICAL COLLEGE – VELLORE

Molecular Genetic Diagnosis of Lipodystrophy Syndromes





Specimen Shipment Details

Delivery accepted Monday to Friday; patient information sheet should accompany all specimens.

MODY genetic testing requisition is accepted only from a qualified healthcare provider.

Specimen Shipment Details

Collect 5 ml of whole blood in purple top EDTA tube. For small babies, we require a minimum of 1 ml of blood.

Ship blood tubes at 4 degrees temperature (frozen ice pack) in an insulated container. Do not freeze blood.

Label the tube with the patient name, date of birth and/or ID number and the center from which the sample is being sent.

Genomic DNA

Send in a sealed tube with at least 20 µg of purified DNA at a concentration of at least 100 ng/µl.

DNA sample can be shipped at room temperature. Include the details of the 260/280 ration which should be around 1.8.

Label the tube with patient's name, date of birth, ID number and name of the referral center.

Shipping Address

Dr. Aaron Chapla M.Sc. Ph.D

Scientist,

Molecular Endocrinology Laboratory,

Department of Endocrinology, Diabetes and Metabolism,

Christian Medical College, Vellore-632004, India

Ph No: 0416 2282181

Email: aaronchapla@gmail.com

For further queries or requests

Dr. Nihal Thomas

MBBS MD MNAMS DNB (Endo) FRACP (Endo) FRCP (Edin) FRCP (Glasg) FRCP (London) Ph.D (Copenhagen)

Professor and Head Unit-I,

Department of Endocrinology, Diabetes and Metabolism

Christian Medical College, Vellore-632004, India

Email: nihal_thomas@yahoo.com

References

- 1. Asha HS, Chapla A, Shetty S, Thomas N (2015) Next-generation sequencing-based genetic testing for familial partial lipodystrophy. AACE Clin Case Rep 1(1):e28–e31
- 2. Shetty S, Chapla A, Kapoor N, Thomas N, Paul TV. A novel variant of the AGPAT2 mutation in generalized congenital lipodystrophy, detected by Next Generation Sequencing. AMJ 2016;9(6):164–168.
- 3. Garg A. Acquired and inherited lipodystrophies. N Engl J Med. 2004;350:1220-1234.
- Brown RJ , Araujo-Vilar D , Cheung PT , Dunger D , Garg A et al ., The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline.
 J Clin Endo. Metab . 2016;101(12):4500–4511.
- 5. RIG Holt, C Cockram, A Flyvbjerg, BJ Goldstein. Textbook of Diabetes. Oxford, U.K., Wiley-Blackwell, 2017